Last $8.74 USD
Change Today -0.13 / -1.47%
Volume 366.6K
PTX On Other Exchanges
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

pernix therapeutics holdings (PTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/12/14 - $11.68
52 Week Low
02/4/14 - $2.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

pernix therapeutics holdings (PTX) Related Businessweek News

No Related Businessweek News Found

pernix therapeutics holdings (PTX) Details

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company’s product include CEDAX, a oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; REZIRA, ZUTRIPRO, and VITUZ, which are oral solutions for the relief of cough and nasal congestion; and OMECLAMOX-PAK to treat patients with H.pylori infection and duodenal ulcer disease. Its products also comprise SILENOR, a prescription medicine used to treat insomnia characterized by difficulty with sleep maintenance; KHEDEZLA, a prescription medicine for the treatment of major depressive disorder; and NATROBA, a prescription medicine used to treat head lice. In addition, the company offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women’s health, pre-natal vitamins, and dental health, as well as allergy, respiratory, iron deficiency, nephrology, and pain management. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was founded in 1996 and is based in Morristown, New Jersey.

191 Employees
Last Reported Date: 03/17/14
Founded in 1996

pernix therapeutics holdings (PTX) Top Compensated Officers

Principal Accounting Officer and Corporate Co...
Total Annual Compensation: $208.3K
Compensation as of Fiscal Year 2013.

pernix therapeutics holdings (PTX) Key Developments

Pernix Therapeutics Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2014

Pernix Therapeutics provided revenue guidance for the fourth quarter and full year ended December 31, 2014. For the fourth quarter, the company expects a 117% year-over-year increase in net revenue for the fourth quarter ended December 31, 2014, which it anticipates would drive its fiscal 2014 revenue to exceed its guidance. The company announced it expects fourth quarter net revenue in excess of $52 million, which represents an increase of 117% from revenue in the same quarter in 2013, and a 65% increase from the third quarter revenues. For the full year 2014, the company sees net revenue in excess of $120 million, which represents an increase of over 40% compared with revenue in fiscal 2013. This would also exceed the top end of the company’s 2014 guidance of $110 million to $120 million.

Pernix Therapeutics Announces FDA Acceptance with Priority Review of TREXIMET® sNDA for Use in Adolescent Patients

Pernix Therapeutics Holdings, Inc. announced that its supplemental New Drug Application (sNDA) for TREXIMET (sumatriptan /naproxen sodium) has been accepted by the U.S. Food and Drug Administration (FDA). Approval is expected in second quarter of 2015, based on the anticipated Prescription Drug User Fee Act (PDUFA) action date. The company’s sNDA, submitted on November 14, 2014 seeks approval for TREXIMET (sumatriptan /naproxen sodium) for use in adolescent patients, age 12 ‘17, for the acute treatment of migraine with or without aura. Included in the filing are safety and efficacy data sets from three trials conducted to evaluate the pharmacokinetic, efficacy, and long-term safety of TREXIMET for the acute treatment of adolescent migraine. To date, there is no sumatriptan or combination prescription medication for the treatment of acute migraine attacks with or without aura approved for use in this population. Presently, TREXIMET is approved in the U.S. for the acute treatment of migraine with or without aura in adults.

Pernix Therapeutics Holdings, Inc.(NasdaqGM:PTX) added to NASDAQ Biotechnology Index

Pernix Therapeutics Holdings, Inc. will be added to the NASDAQ Biotechnology Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTX:US $8.74 USD -0.13

PTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Interpharm Holdings Inc $0.0000 USD 0.00
OraSure Technologies Inc $9.90 USD -0.13
ProPhase Labs Inc $1.61 USD +0.03
SciClone Pharmaceuticals Inc $7.37 USD 0.00
Sucampo Pharmaceuticals Inc $15.97 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation PTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERNIX THERAPEUTICS HOLDINGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at